Repligen (RGEN) News Today

$171.94
+0.91 (+0.53%)
(As of 05/17/2024 ET)
Repligen Co. (NASDAQ:RGEN) Stock Holdings Increased by Wafra Inc.
Wafra Inc. boosted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 75.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,862 shares of the biotechnology company's stock after purchasin
Principal Financial Group Inc. Increases Stock Position in Repligen Co. (NASDAQ:RGEN)
Principal Financial Group Inc. raised its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 36.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 262,708 shares of the biotechnology company's stock af
Los Angeles Capital Management LLC Buys New Position in Repligen Co. (NASDAQ:RGEN)
Los Angeles Capital Management LLC purchased a new position in Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 5,368 shares of the biotechnology company's stock, valued at approximately $965,000. A number of o
TimesSquare Capital Management LLC Boosts Position in Repligen Co. (NASDAQ:RGEN)
TimesSquare Capital Management LLC grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 61.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 205,883 shares of the biotechnology company's stock aft
Lisanti Capital Growth LLC Sells 11,715 Shares of Repligen Co. (NASDAQ:RGEN)
Lisanti Capital Growth LLC cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 82.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,425 shares of the biotechnology company's stock after selling 11,715 shares during the period. Lisa
International Assets Investment Management LLC Buys 58,299 Shares of Repligen Co. (NASDAQ:RGEN)
International Assets Investment Management LLC lifted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 18,449.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,615 shares of the biotechnology comp
Van ECK Associates Corp Has $8.37 Million Stake in Repligen Co. (NASDAQ:RGEN)
Van ECK Associates Corp cut its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 14.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,536 shares of the biotechnology company's stock af
Repligen Co. Expected to Post Q2 2024 Earnings of $0.33 Per Share (NASDAQ:RGEN)
Repligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2024 earnings per share estimates for shares of Repligen in a note issued to investors on Wednesday, May 1st. Leerink Partnrs analyst P. Souda now expects that the biotechnology company wil
Repligen (NASDAQ:RGEN) Issues Earnings Results
Repligen (NASDAQ:RGEN - Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01). The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company's revenue was down 17.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.64 EPS.
Repligen (NASDAQ:RGEN) Price Target Cut to $200.00 by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. dropped their target price on shares of Repligen from $230.00 to $200.00 and set an "overweight" rating on the stock in a report on Thursday.
Repligen (NASDAQ:RGEN) Issues FY 2024 Earnings Guidance
Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.460. The company also issued revenue guidance of $620.0 millionillion-$650.0 millionillion, compared to the consensus estimate of $635.6 millionillion.
RGEN Quantitative Stock Analysis
Repligen Co. (NASDAQ:RGEN) Stake Cut by New York State Common Retirement Fund
New York State Common Retirement Fund cut its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 425,412 shares of the biotechnology company's stock after se
Positive Report for Repligen (RGEN) from Craig-Hallum
Federated Hermes Inc. Cuts Stake in Repligen Co. (NASDAQ:RGEN)
Federated Hermes Inc. lowered its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 11.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 396,568 shares of the biotechnology company's stock after selling 49,325 shares during
Repligen Corporation Common Stock (RGEN)
14,600 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by Louisiana State Employees Retirement System
Louisiana State Employees Retirement System bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,600 shares of the biotechnology
London & Capital Asset Management Ltd Acquires 6,215 Shares of Repligen Co. (NASDAQ:RGEN)
London & Capital Asset Management Ltd boosted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,619 shares of the biotechnology company's stoc
International Assets Investment Management LLC Grows Position in Repligen Co. (NASDAQ:RGEN)
International Assets Investment Management LLC boosted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 18,449.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 58,615 shares of the biotechnology company's stock after purchasing an
Repligen Co. (NASDAQ:RGEN) Shares Bought by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC raised its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 5.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,933 shares of the biotechnology com
Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from Brokerages
Repligen Co. (NASDAQ:RGEN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. Th
Repligen Co. (NASDAQ:RGEN) Shares Sold by Impax Asset Management Group plc
Impax Asset Management Group plc decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 6.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 912,821 shares of the biotechnology co
RBC Capital Remains a Buy on Repligen (RGEN)
Raymond James & Associates Sells 20,495 Shares of Repligen Co. (NASDAQ:RGEN)
Raymond James & Associates reduced its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 30.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,724 shares of the biotechnology company's st
Repligen Co. (NASDAQ:RGEN) Shares Sold by Riverbridge Partners LLC
Riverbridge Partners LLC trimmed its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 409,333 shares of the biotechnology company's stock after selling 8,423
SG Americas Securities LLC Has $1.27 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)
SG Americas Securities LLC trimmed its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 74.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,042 shares of the biotechnology company's s
Artemis Investment Management LLP Makes New Investment in Repligen Co. (NASDAQ:RGEN)
Artemis Investment Management LLP bought a new position in Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 125,433 shares of the biotechnology company's stock, valued at approximately $22,55
Repligen (NASDAQ:RGEN) Trading Down 2.3%
Repligen (NASDAQ:RGEN) Trading Down 2.3%
Handelsinvest Investeringsforvaltning Sells 17,821 Shares of Repligen Co. (NASDAQ:RGEN)
Handelsinvest Investeringsforvaltning lessened its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 89.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,179 shares of the biotechnology company's stock
Repligen Appoints Maggie A. Pax to Board of Directors
American Century Companies Inc. Has $34.65 Million Holdings in Repligen Co. (NASDAQ:RGEN)
American Century Companies Inc. raised its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 97.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 217,900 shares of the biotechnology company
Repligen Co. (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Analysts
Repligen Co. (NASDAQ:RGEN - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company.
Zacks Research Analysts Lower Earnings Estimates for Repligen Co. (NASDAQ:RGEN)
Repligen Co. (NASDAQ:RGEN - Free Report) - Research analysts at Zacks Research decreased their Q3 2024 earnings per share (EPS) estimates for Repligen in a research report issued on Wednesday, March 13th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $
Get Repligen News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (Ad)

Man who spotted Apple at $1.49 says: "Buy These 6 AI Stocks."

And these will be the biggest winners

RGEN Media Mentions By Week

RGEN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RGEN
News Sentiment

1.05

0.43

Average
Medical
News Sentiment

RGEN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RGEN Articles
This Week

4

5

RGEN Articles
Average Week

Get Repligen News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RGEN) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners